Larimar Therapeutics Inc (LRMR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $313.73M
Last updated: Nov 17, 2026 at 11:06 AM ET
Larimar Therapeutics Inc (LRMR) Earnings: Report Dates and Results
Larimar Therapeutics (LRMR) is expected to report earnings on Mar 17, 2027. In the quarter ended Sep 30, 2026, Larimar Therapeutics reported EPS of -$0.61, below the -$0.35 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
LRMR has an expected report date of Mar 17, 2027.
Earnings History
Of the 40 quarters below that had an estimate, LRMR beat 26, missed 13 and matched 1. The widest gap in the table came in the quarter ended Sep 30, 2026, when EPS landed 74.29% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.61 | -$0.35 | -$0.41 - -$0.31 | -74.29% | Miss | N/A | 8 | 6 up, 0 down | Nov 11, 2026 |
| Jun 30, 2026 | -$0.30 | -$0.39 | -$0.48 - -$0.33 | +23.08% | Beat | N/A | 8 | N/A | Aug 4, 2026 |
| Mar 31, 2026 | -$0.31 | -$0.59 | -$0.74 - -$0.40 | +47.46% | Beat | N/A | 5 | 0 up, 3 down | May 14, 2026 |
| Dec 31, 2025 | -$0.73 | -$0.49 | -$0.67 - -$0.41 | -48.98% | Miss | N/A | 7 | 0 up, 3 down | Mar 19, 2026 |
| Sep 30, 2025 | -$0.61 | -$0.39 | -$0.50 - -$0.36 | -56.41% | Miss | N/A | 8 | 6 up, 1 down | Nov 5, 2025 |
| Jun 30, 2025 | -$0.41 | -$0.49 | -$0.51 - -$0.46 | +16.33% | Beat | N/A | 7 | 1 up, 0 down | Aug 14, 2025 |
| Mar 31, 2025 | -$0.46 | -$0.41 | -$0.46 - -$0.35 | -12.20% | Miss | N/A | 7 | 1 up, 3 down | Apr 30, 2025 |
| Dec 31, 2024 | -$0.45 | -$0.32 | -$0.45 - -$0.25 | -40.89% | Miss | N/A | 10 | 1 up, 0 down | Mar 24, 2025 |
| Sep 30, 2024 | -$0.24 | -$0.37 | -$0.42 - -$0.29 | +35.14% | Beat | N/A | 11 | 0 up, 0 down | Oct 30, 2024 |
| Jun 30, 2024 | -$0.34 | -$0.32 | -$0.35 - -$0.26 | -6.25% | Miss | N/A | 6 | 0 up, 0 down | Aug 7, 2024 |
| Mar 31, 2024 | -$0.27 | -$0.24 | -$0.25 - -$0.21 | -12.50% | Miss | N/A | 4 | 0 up, 0 down | May 9, 2024 |
| Dec 31, 2023 | -$0.30 | -$0.25 | -$0.28 - -$0.22 | -20.00% | Miss | N/A | 5 | 0 up, 0 down | Mar 14, 2024 |
| Sep 30, 2023 | -$0.21 | -$0.23 | -$0.27 - -$0.20 | +8.70% | Beat | N/A | 5 | 0 up, 0 down | Nov 14, 2023 |
| Jun 30, 2023 | -$0.19 | -$0.21 | -$0.27 - -$0.15 | +9.52% | Beat | N/A | 5 | 0 up, 0 down | Aug 10, 2023 |
| Mar 31, 2023 | -$0.15 | -$0.25 | -$0.26 - -$0.23 | +40.00% | Beat | N/A | 4 | 0 up, 0 down | May 15, 2023 |
| Dec 31, 2022 | -$0.21 | -$0.37 | -$0.78 - -$0.21 | +43.24% | Beat | N/A | 5 | 0 up, 0 down | Mar 14, 2023 |
| Sep 30, 2022 | -$0.37 | -$0.42 | -$0.77 - -$0.20 | +11.90% | Beat | N/A | 4 | 0 up, 0 down | Nov 10, 2022 |
| Jun 30, 2022 | -$0.47 | -$0.57 | N/A | +17.54% | Beat | N/A | N/A | 0 up, 0 down | Aug 11, 2022 |
| Mar 31, 2022 | -$0.49 | -$0.51 | -$0.51 - -$0.51 | +3.92% | Beat | N/A | 2 | 0 up, 0 down | May 12, 2022 |
| Dec 31, 2021 | -$0.50 | -$0.72 | -$0.96 - -$0.43 | +30.56% | Beat | N/A | 3 | N/A | Mar 25, 2022 |
| Sep 30, 2021 | -$0.92 | -$0.66 | -$0.69 - -$0.60 | -39.39% | Miss | N/A | 3 | 1 up, 0 down | Nov 12, 2021 |
| Jun 30, 2021 | -$0.79 | -$0.75 | -$0.78 - -$0.70 | -5.33% | Miss | N/A | 3 | N/A | Aug 12, 2021 |
| Mar 31, 2021 | -$0.76 | -$0.86 | -$0.93 - -$0.80 | +11.63% | Beat | N/A | 2 | N/A | May 10, 2021 |
| Dec 31, 2020 | -$0.89 | -$0.70 | N/A | -27.14% | Miss | N/A | N/A | N/A | Mar 4, 2021 |
| Sep 30, 2020 | -$0.64 | -$2.28 | N/A | +71.93% | Beat | N/A | N/A | N/A | Nov 10, 2020 |
| Jun 30, 2020 | -$1.21 | -$2.16 | N/A | +43.98% | Beat | N/A | N/A | N/A | Aug 11, 2020 |
| Mar 31, 2020 | -$1.20 | -$2.28 | N/A | +47.37% | Beat | N/A | N/A | N/A | May 8, 2020 |
| Dec 31, 2019 | -$2.28 | -$2.28 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 5, 2020 |
| Sep 30, 2019 | -$2.88 | -$3.20 | N/A | +10.00% | Beat | N/A | N/A | N/A | Nov 6, 2019 |
| Jun 30, 2019 | -$3.84 | -$4.38 | N/A | +12.33% | Beat | N/A | N/A | N/A | Aug 8, 2019 |
| Mar 31, 2019 | -$4.20 | -$5.09 | N/A | +17.49% | Beat | N/A | N/A | N/A | May 9, 2019 |
| Dec 31, 2018 | -$4.68 | -$5.26 | N/A | +11.03% | Beat | N/A | N/A | N/A | Mar 11, 2019 |
| Sep 30, 2018 | -$4.92 | -$5.64 | N/A | +12.77% | Beat | N/A | N/A | N/A | Nov 7, 2018 |
| Jun 30, 2018 | -$6.84 | -$7.08 | N/A | +3.39% | Beat | N/A | N/A | N/A | Aug 7, 2018 |
| Mar 31, 2018 | -$6.96 | -$6.18 | N/A | -12.62% | Miss | N/A | N/A | N/A | May 8, 2018 |
| Dec 31, 2017 | -$5.76 | -$6.84 | N/A | +15.79% | Beat | N/A | N/A | N/A | Mar 6, 2018 |
| Sep 30, 2017 | -$5.52 | -$6.92 | N/A | +20.23% | Beat | N/A | N/A | N/A | Nov 7, 2017 |
| Jun 30, 2017 | -$5.88 | -$6.24 | N/A | +5.77% | Beat | N/A | N/A | N/A | Aug 8, 2017 |
| Mar 31, 2017 | -$5.76 | -$5.21 | N/A | -10.56% | Miss | N/A | N/A | N/A | May 9, 2017 |
| Dec 31, 2016 | -$4.56 | -$6.03 | N/A | +24.38% | Beat | N/A | N/A | N/A | Mar 9, 2017 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$2.21, after -$1.30 the year before. It was -$25.44 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$2.21 | N/A |
| Dec 31, 2024 | -$1.30 | N/A |
| Dec 31, 2023 | -$0.85 | N/A |
| Dec 31, 2022 | -$1.54 | N/A |
| Dec 31, 2021 | -$2.97 | N/A |
| Dec 31, 2020 | -$3.94 | N/A |
| Dec 31, 2019 | -$13.20 | N/A |
| Dec 31, 2018 | -$23.40 | N/A |
| Dec 31, 2017 | -$22.92 | N/A |
| Dec 31, 2016 | -$25.44 | N/A |
Frequently Asked Questions About LRMR
When is Larimar Therapeutics's next earnings date?
Larimar Therapeutics's next earnings report is expected for Mar 17, 2027.
Did LRMR beat earnings estimates last quarter?
No. Larimar Therapeutics reported EPS of -$0.61 for the quarter ended Sep 30, 2026, below the -$0.35 estimate by 74.29%.
What EPS do analysts expect from LRMR next quarter?
The consensus EPS estimate for Larimar Therapeutics for the quarter ending Dec 31, 2026 is -$0.38 from 13 analysts, with estimates from -$0.44 to -$0.33.
How often does LRMR beat earnings estimates?
Larimar Therapeutics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -18.24%.
LRMR pages: Overview, Earnings, Forecast, Financials, Competitors